文献速递炎症性肠病

克罗恩病临床前期的免疫应答与屏障功能障碍相关蛋白质组特征揭示最早发病事件

Immune response and barrier dysfunction-related proteomic signatures in preclinical phase of Crohn's disease highlight earliest events of pathogenesis.
PubMed 文献 · Gut · 2023-02-14

在CCC-GEM队列中嵌套病例对照研究,71例未来发生克罗恩病的健康一级亲属与284名保持健康者匹配,发现25种血清蛋白与未来发病显著相关;CXCL9的OR最高(每SD OR=2.07),且与粪钙卫蛋白、乳果糖/甘露醇比值及抗菌抗体均显著相关,提示免疫与屏障功能障碍是早期事件。

要点

  • 临床前克罗恩病血清蛋白质组中25/446种蛋白与未来发病显著相关。
  • CXCL9与未来克罗恩病风险关联最强(每SD OR=2.07,95%CI 1.58–2.73)。
  • CXCL9与粪钙卫蛋白、肠道屏障功能及抗菌抗体均呈一致方向关联。

核心结论

  • 血清蛋白质组特征与未来克罗恩病发病相关,反映免疫与屏障功能障碍的潜在早期生物学过程。

研究设计与样本

  • 在克罗恩病与结肠炎加拿大遗传环境微生物项目(CCC-GEM)前瞻性随访健康一级亲属的队列中开展嵌套病例对照研究。
  • 未来发生克罗恩病者71例,与284名保持健康的一级亲属匹配。
  • 采用Olink邻近延伸分析平台检测入组时血清蛋白谱,并与未来克罗恩病发病及基线生物标志物进行关联分析。

主要发现

  • 446种血清蛋白中25种与未来克罗恩病发病显著相关。
  • C-X-C基序趋化因子9(CXCL9)与未来克罗恩病风险关联的OR最高(每SD OR=2.07,95%CI 1.58–2.73,q=7.9e-5)。
  • 基质细胞外磷酸糖蛋白与未来克罗恩病风险关联的OR最低(OR=0.44,95%CI 0.29–0.66,q=0.02)。
  • CXCL9是唯一与所有其他克罗恩病风险生物标志物均显著相关且效应方向一致的指标(粪钙卫蛋白:OR=2.21;乳果糖/甘露醇比值:OR=1.67;抗菌抗体评分:OR=1.59;q均<0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The measure of serum proteome in the preclinical state of Crohn's disease (CD) may provide insight into biological pathways involved in CD pathogenesis. We aimed to assess associations of serum proteins with future CD onset and with other biomarkers predicting CD risk in a healthy at-risk cohort. DESIGN: In a nested case-control study within the Crohn's and Colitis Canada Genetics Environment Microbial Project (CCC-GEM) cohort, which prospectively follows healthy first-degree relatives (FDRs), subjects who developed CD (n=71) were matched with four FDRs remaining healthy (n=284). Using samples at recruitment, serum protein profiles using the Olink Proximity Extension Assay platform was assessed for association with future development of CD and with other baseline biomarkers as follows: serum antimicrobial antibodies (AS: positive antibody sum) (Prometheus); faecal calprotectin (FCP); gut barrier function using the fractional excretion of lactulose-to-mannitol ratio (LMR) assay. RESULTS: We identified 25 of 446 serum proteins significantly associated with future development of CD. C-X-C motif chemokine 9 (CXCL9) had the highest OR with future risk of CD (OR=2.07 per SD, 95% CI 1.58 to 2.73, q=7.9e-5), whereas matrix extracellular phosphoglycoprotein had the lowest OR (OR 0.44, 95% CI 0.29 to 0.66, q=0.02). Notably, CXCL9 was the only analyte significantly associated with all other CD-risk biomarkers with consistent direction of effect (FCP: OR=2.21; LMR: OR=1.67; AS: OR=1.59) (q<0.05 for all). CONCLUSION: We identified serum proteomic signatures associated with future CD development, reflecting potential early biological processes of immune and barrier dysfunction.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Leibovitzh H, Lee SH, Raygoza Garay JA, et al. Immune response and barrier dysfunction-related proteomic signatures in preclinical phase of Crohn's disease highlight earliest events of pathogenesis. Gut. 2023. PMID: 36788016. doi:10.1136/gutjnl-2022-328421

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。